Literature DB >> 12706407

Impaired NK cell differentiation of blood-derived CD34+ progenitors from patients with myeloid metaplasia with myelofibrosis.

Diane Briard1, Danièle Brouty-Boyé, Julien Giron-Michel, Bruno Azzarone, Claude Jasmin, Caroline Le Bousse-Kerdilès.   

Abstract

Cultured blood CD34(+) progenitors from patients with myeloid metaplasia with myelofibrosis (MMM) failed to differentiate into natural killer (NK) cells with recombinant interleukin (IL)-15. No NK cells either could be induced in coculture with IL-15-expressing fibroblasts from MMM patients' spleens. The impaired NK differentiation could be circumvented by using normal blood CD34(+) cells in the coculture. In this case, cell-to-cell contact and IL-15 interaction were crucial for NK cell differentiation. Pretreatment of normal CD34(+) progenitors with anti-IL-15 monoclonal antibody markedly reduced NK cell production while MMM fibroblast pretreatment did not. Both normal and MMM progenitors constitutively expressed IL-15. Analysis of endogenous IL-15 signaling pathway revealed a constitutive gammac/Jak3 association and STAT3 activation in the two types of progenitors. Anti-IL-15 monoclonal antibody treatment caused a downregulation of IL-15 signaling in normal but not MMM blood cells. The impaired NK differentiation in MMM may thus arise from a deregulated control of an endogenous IL-15 involved in hematopoietic progenitors' lymphoid differentiation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12706407     DOI: 10.1016/s1521-6616(02)00046-3

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  7 in total

1.  Importance of stromal determinants in the generation of dendritic and natural killer cells in the human spleen.

Authors:  D Briard; B Azzarone; D Brouty-Boyé
Journal:  Clin Exp Immunol       Date:  2005-05       Impact factor: 4.330

2.  Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis.

Authors:  Lilian Varricchio; Annalisa Mancini; Anna Rita Migliaccio
Journal:  Expert Rev Hematol       Date:  2009-06-01       Impact factor: 2.929

3.  Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis.

Authors:  Marco Romano; Daria Sollazzo; Sara Trabanelli; Martina Barone; Nicola Polverelli; Margherita Perricone; Dorian Forte; Simona Luatti; Michele Cavo; Nicola Vianelli; Camilla Jandus; Francesca Palandri; Lucia Catani
Journal:  Oncoimmunology       Date:  2017-07-05       Impact factor: 8.110

Review 4.  Harnessing Unconventional T Cells and Innate Lymphoid Cells to Prevent and Treat Hematological Malignancies: Prospects for New Immunotherapy.

Authors:  Alessandro Allegra; Marco Casciaro; Elena Lo Presti; Caterina Musolino; Sebastiano Gangemi
Journal:  Biomolecules       Date:  2022-05-27

Review 5.  PD-1/PD-L1, MDSC Pathways, and Checkpoint Inhibitor Therapy in Ph(-) Myeloproliferative Neoplasm: A Review.

Authors:  Jen-Chin Wang; Lishi Sun
Journal:  Int J Mol Sci       Date:  2022-05-23       Impact factor: 6.208

Review 6.  Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone.

Authors:  J-J Kiladjian; S Giraudier; B Cassinat
Journal:  Leukemia       Date:  2015-11-25       Impact factor: 11.528

7.  The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis.

Authors:  Martina Barone; Lucia Catani; Francesca Ricci; Marco Romano; Dorian Forte; Giuseppe Auteri; Daniela Bartoletti; Emanuela Ottaviani; Pier Luigi Tazzari; Nicola Vianelli; Michele Cavo; Francesca Palandri
Journal:  Oncoimmunology       Date:  2020-06-23       Impact factor: 8.110

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.